Skip to main content

Table 4 HR estimates of overall survival* by TP53 R72P, MDM2 SNP309 and p53

From: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

TP53R72P** HR Lower and upper limit 95% CI Pvalue
ABCS     
   GC 0.99 0.79 1.26 0.95
   CC 0.72 0.45 1.16 0.17
HABCS     
   GC 1.40 0.60 3.45 0.46
   CC 2.54 0.69 9.34 0.16
HEBCS     
   GC 1.17 0.82 1.67 0.40
   CC 1.72 1.00 2.98 0.05
SEARCH     
   GC 1.18 0.95 1.49 0.14
   CC 0.93 0.59 1.48 0.77
Pooled     
   GC 1.11 0.96 1.28 0.18
   CC 1.00 0.76 1.31 0.97
MDM2 SNP309**     
ABCS     
   TG 0.93 0.73 1.18 0.54
   GG 0.99 0.70 1.40 0.97
HABCS     
   TG 0.60 0.25 1.46 0.26
   GG 0.36 0.08 1.65 0.19
HEBCS     
   TG 0.76 0.53 1.11 0.16
   GG 0.91 0.56 1.47 0.69
SEARCH     
   TG 1.03 0.82 1.31 0.78
   GG 1.43 1.03 1.97 0.03
Pooled     
   TG 0.93 0.80 1.08 0.34
   GG 1.11 0.90 1.37 0.31
p53 status tumor **     
ABCS     
   p53 positive 1.31 0.96 1.80 0.09
HEBCS     
   p53 positive 1.93 1.27 2.94 0.002
Pooled     
   p53 positive 1.50 1.16 1.93 0.002
Breast cancer-specific survival
Pooled
    
   p53 positive 1.57 1.20 2.05 0.001
  1. *Overall survival including all studies unless otherwise specified; ** HRs of heterozygous and homozygous rare allele groups have been calculated by comparison to the reference categories of common alleles: TP53 R72P = GG; MDM2 SNP309 = TT; p53 = negative tumors; Pooled analyses have been adjusted for study.